Allakos, Inc.
(NASDAQ : ALLK)

( )
ALLK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.47%38.450.9%$1234.07m
JNJJohnson & Johnson 0.73%148.630.7%$874.96m
MRKMerck & Co., Inc. -0.05%81.010.7%$634.52m
ABBVAbbVie, Inc. 0.40%92.941.9%$597.83m
BMYBristol-Myers Squibb Co. -0.52%61.011.0%$597.21m
AZNAstraZeneca Plc -1.44%55.401.2%$564.41m
LLYEli Lilly & Co. 0.06%152.971.1%$430.35m
NVSNovartis AG -0.56%82.940.2%$140.44m
GSKGlaxoSmithKline Plc -0.43%40.800.2%$136.90m
MISTMilestone Pharmaceuticals, Inc. 11.36%9.800.0%$133.95m
OPKOPKO Health, Inc. -0.44%5.6311.2%$132.17m
NVONovo Nordisk A/S 1.49%64.640.1%$68.87m
RGENRepligen Corp. -1.23%152.777.2%$68.82m
PRNBPrincipia Biopharma, Inc. 5.33%91.890.0%$63.33m
SNYSanofi 0.02%51.510.2%$55.59m

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.